Leveraging a Clinical Phase Ib Proof ‐of‐Concept Study for the GPR40 Agonist MK‐8666 in Patients With Type 2 Diabetes for Model‐Informed Phase II Dose Selection

In conclusion, MK‐8666 was generally well tolerated with robust glucose‐lowering efficacy.

Source: Clinical and Translational Science - July 1, 2017 Category: Biomedical Science Authors: AW Krug, P Vaddady, RA Railkar, BJ Musser, J Cote, AGH Ederveen, DG Krefetz, E DeNoia, AL Free, L Morrow, MV Chakravarthy, E Kauh, DA Tatosian, PA Kothare Tags: ARTICLE Source Type: research